New data from Eli Lilly says its daily, oral GLP-1 pill may help people who have obesity and people who have Type 2 diabetes ...

Lilly said it’s moving ‘with urgency toward global regulatory submissions to potentially meet the needs of patients who are ...

Like semaglutide, the new drug known as ecnoglutide is glucagon-like peptide-1 receptor agonist. In simple terms, they both ...

The latest results from a trial of a pill form popular GLP-1 medications offer enough information for the Eli Lilly to ...

A relatively old drug -- metformin -- may hold the key to preventing life-threatening illness and bolstering human longevity, ...

New recommendations suggest holding back on SGLT2 inhibitors and GLP-1s among those at a lower risk for cardiovascular or ...

Ecnoglutide, a novel once-weekly injection for type 2 diabetes management, works as well as dulaglutide (a commonly ...

It’s part of a new class of drugs that includes semaglutide, known as Ozempic for diabetes and Wegovy for weight loss, which have skyrocketed in popularity in recent years.

A recent clinical trial revealed that the new weight loss drug, ecnoglutide, outperformed existing treatment dulaglutide in managing type 2 diabetes and obesity.

In other studies, people with diabetes who used the medication only lost an average of 15% of their body weight, noted Gabbay. “This is a not an uncommon observation,” he said.

When you buy through links on our articles, Future and its syndication partners may earn a commission.